123 Main Street, New York, NY 10001

Top Navigation with Mega Menu
Investor Relations
Co-Diagnostics, Inc. Reports Full Year 2022 Financial Results

Full-year Results Impacted by Lower Demand for COVID-19 Testing
Announced Initiation of Clinical Evaluations for Co-Dx PCR Home™ Platform

SALT LAKE CITY, March 16, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the full year ended December 31, 2022.

Full Year 2022 Financial Results:

  • Revenue of $34.2 million, down from $97.9 million during the prior year primarily due to lower global demand for the Logix Smart™ COVID-19 tests
  • Gross profit of $28.7 million, representing 84.0% of consolidated revenue
  • Operating loss of $27.0 million compared to operating income of $46.1 million a year ago, due to lower revenue, goodwill impairment charges, and continued investments into research and development for the Co-Dx PCR Home Platform
  • Net loss of $14.2 million, compared to net income of $36.7 million in the prior year, representing loss of $0.45 per fully diluted share, compared to $1.23 in 2021
  • Adjusted net income, net of goodwill impairment charges, of $1.2 million, compared to adjusted net income of $36.7 million in the prior year, representing adjusted income of $0.04 per fully diluted share, compared to $1.23 in 2021
  • Adjusted EBITDA loss of $3.1 million
  • Repurchased 3.9 million shares of common stock at an average price of $3.66 per share for an aggregate purchase price of approximately $14.2 million
  • Cash, cash equivalents, and marketable securities of $81.3 million as of December 31, 2022
  • Cash flow from operations of $6.6 million for the twelve months ended December 31, 2022

Dwight Egan, Co-Diagnostics' Chief Executive Officer, said, "The impact of COVID-19 on society decreased considerably during the second half of the year, and resulted in lower demand for high-throughput testing at the centralized lab level. While our overall financial performance has been impacted by these trends, we are pleased with the progress we made against our strategic priorities which support our Co-Dx PCR Home™ platform as we continue to see an emphasis on diagnostics shifting out of the centralized lab settings and towards at-home and point-of-care (POC). The commencement of clinical evaluations announced in February of this year marks an important step toward detection of infectious diseases in at-home and POC settings, with anticipated multiplex panels to follow."

Mr. Egan continued, "Looking ahead, we remain focused on executing the clinical evaluations for our Co-Dx PCR Home platform, including the clinical trials themselves and the analytical studies required to support regulatory submissions. Our mission of creating a new standard for real-time PCR at-home and POC technology continues to be validated. We firmly believe our patented Co-Primers™ technology and patent-pending design of the new Co-Dx PCR Home platform extend our capabilities, aspirations, and potential far beyond COVID-19, and we continue our focus on managing the business and being deliberate in our actions."

Full Year 2022 and Recent Business Highlights:

  • Expanded the OEM agreement with Bio Molecular Systems for the Co-Dx Box™ magnetic induction PCR cycler to encompass 193 countries worldwide
  • Designed and verified two testing products for mpox in response to urgent global health concern generated by that virus
  • Received clearance from Indian regulators for JV CoSara hepatitis B and hepatitis C viral load tests, as well as a high-risk HPV multiplex test
  • Authorized a $30.0 million share repurchase program
  • Recently initiated clinical evaluations for Co-Dx PCR Home platform and initial COVID-19 test
  • Completed strategic additions to the Scientific Advisory Board appointing Carl Wittwer, M.D., Ph.D. as Chairman, as well as Karen C. Carroll, M.D, Noriko Kusukawa, Ph.D., and Anne Wyllie, Ph.D.

Conference Call and Webcast

Co-Diagnostics will host a conference call and webcast at 4:30 p.m. EDT today to discuss its financial results with analysts and institutional investors. The conference call and webcast will be available via:

Webcast: ir.codiagnostics.com on the Events & Webcasts page

Conference Call: 844-481-2661 (domestic) or 412-317-0652 (international)

The call will be recorded and later made available on the Company's website: https://codiagnostics.com

*The Co-Dx PCR Home platform is subject to FDA review and is not currently for sale.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR Home™ platform and to locate genetic markers for use in applications other than infectious disease.

Non-GAAP Financial Measures:

This press release contains adjusted EBITDA, which is a non-GAAP measure defined as net income excluding depreciation, amortization, income tax (benefit) expense, net interest (income) expense, stock-based compensation, and one-time transaction related costs. Additionally, this press release contains adjusted net income (loss), which is a non-GAAP measure defined as net income excluding goodwill impairment charges. The Company believes that adjusted EBITDA and adjusted net income (loss) provide useful information to management and investors relating to its results of operations. The Company's management uses these non-GAAP measures to compare the Company's performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The Company believes that the use of adjusted EBITDA and adjusted net income (loss) provide an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company's financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making.

Management does not consider the non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of the non-GAAP financial measures is that they exclude significant expenses that are required by GAAP to be recorded in the Company's financial statements. In order to compensate for these limitations, management presents the non-GAAP financial measures together with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. Reconciliation tables of the net income, the most comparable GAAP financial measure, to adjusted EBITDA and adjusted net income (loss) are included at the end of this release. The Company urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the company's business.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding (i) that we continue to see an emphasis on diagnostics shifting out of the centralized lab settings and towards at-home and point-of-care settings, (ii)anticipated development of multiplex panels, and (iii) that we will successfully complete the clinical trials required to support regulatory submissions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 24, 2022, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

 

CO-DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

 
   
   

December 31,
2022

   

December 31,
2021

 

Assets

               

Current assets

               

Cash and cash equivalents

 

$

22,973,803

   

$

88,607,234

 

Marketable investment securities

   

58,289,066

     

1,255,266

 

Accounts receivable, net

   

3,453,723

     

20,839,182

 

Inventory

   

5,310,473

     

2,004,169

 

Income taxes receivable

   

1,870,419

     

-

 

Prepaid expenses and other current assets

   

761,186

     

2,338,444

 

Note receivable

   

75,000

     

75,000

 

Total current assets

   

92,733,670

     

115,119,295

 

Property and equipment, net

   

2,539,483

     

1,933,216

 

Operating lease right-of-use asset

   

372,115

     

-

 

Goodwill

   

-

     

14,706,818

 

Intangible assets, net

   

26,768,333

     

27,195,000

 

Investment in joint venture

   

672,679

     

1,004,953

 

Note receivable

   

-

     

75,000

 

Total assets

 

$

123,086,280

   

$

160,034,282

 

Liabilities and stockholders' equity

               

Current liabilities

               

Accounts payable

 

$

952,297

   

$

607,506

 

Accrued expenses, current

   

934,447

     

3,859,652

 

Operating lease liability, current

   

297,209

     

-

 

Contingent consideration liabilities, current

   

1,689,471

     

5,767,304

 

Income taxes payable

   

-

     

2,213,088

 

Deferred revenue

   

-

     

150,000

 

Total current liabilities

   

3,873,424

     

12,597,550

 

Long-term liabilities

               

Income taxes payable

   

1,181,284

     

1,067,853

 

Deferred tax liability

   

2,417,987

     

7,228,444

 

Operating lease liability

   

50,708

     

-

 

Contingent consideration liabilities

   

1,042,885

     

4,665,337

 

Total long-term liabilities

   

4,692,864

     

12,961,634

 

Total liabilities

   

8,566,288

     

25,559,184

 

Commitments and contingencies (Note 13)

               

Stockholders' equity

               

Convertible preferred stock, $0.001 par value; 5,000,000 shares

authorized; 0 shares issued and outstanding as of December 31, 2022

and December 31, 2021, respectively

   

-

     

-

 

Common stock, $0.001 par value; 100,000,000 shares authorized;

34,754,265 shares issued and 30,872,607 shares outstanding as of

December 31, 2022 and 33,819,862 shares issued and outstanding

as of December 31, 2021

   

34,754

     

33,820

 

Treasury stock, at cost; 3,881,658 and 0 shares held as of December

31, 2022 and December 31, 2021, respectively

   

(14,211,866)

     

-

 

Additional paid-in capital

   

88,472,934

     

80,271,999

 

Accumulated other comprehensive income

   

293,140

     

-

 

Accumulated earnings

   

39,931,030

     

54,169,279

 

Total stockholders' equity

   

114,519,992

     

134,475,098

 

Total liabilities and stockholders' equity

 

$

123,086,280

   

$

160,034,282

 

 

CO-DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

 
   

Years Ended December 31,

 
   

2022

   

2021

 

Revenue

 

$

34,218,209

   

$

97,885,603

 

Cost of revenue

   

5,481,092

     

11,574,944

 

Gross profit

   

28,737,117

     

86,310,659

 

Operating expenses

               

Sales and marketing

   

7,344,628

     

13,397,813

 

General and administrative

   

14,262,963

     

11,550,615

 

Research and development

   

17,438,098

     

14,961,916

 

Depreciation and amortization

   

1,282,718

     

335,363

 

Goodwill impairment charges

   

15,388,546

     

-

 

Total operating expenses

   

55,716,953

     

40,245,707

 

Income (loss) from operations

   

(26,979,836)

     

46,064,952

 

Other income (expense)

               

Interest income

   

704,044

     

45,631

 

Loss on disposition of assets

   

(138,117)

     

(44,355)

 

Gain on remeasurement of acquisition contingencies

   

7,899,644

     

-

 

Loss on equity method investment in joint venture

   

(332,969)

     

(430,433)

 

Total other income (expense)

   

8,132,602

     

(429,157)

 

Income (loss) before income taxes

   

(18,847,234)

     

45,635,795

 

Income tax provision (benefit)

   

(4,608,985)

     

8,977,231

 

Net income (loss)

 

$

(14,238,249)

   

$

36,658,564

 

Other comprehensive income

               

Change in net unrealized gains on marketable securities, net of tax

 

$

293,140

   

$

-

 

Total other comprehensive income

 

$

293,140

   

$

-

 

Comprehensive income (loss)

 

$

(13,945,109)

   

$

36,658,564

 
                 

Earnings per common share:

               

Basic

 

$

(0.45)

   

$

1.27

 

Diluted

 

$

(0.45)

   

$

1.23

 

Weighted average shares outstanding:

               

Basic

   

31,479,028

     

28,874,555

 

Diluted

   

31,479,028

     

29,903,686

 

 

CO-DIAGNOSTICS, INC. AND SUBSIDIARIES

GAAP AND NON-GAAP MEASURES

 

Reconciliation of net income to adjusted EBITDA: 

 
   

Years Ended December 31,

 
   

2022

   

2021

 

Net income (loss)

 

$

(14,238,249)

   

$

36,658,564

 

Interest income

   

(704,044)

     

(45,631)

 

Depreciation and amortization

   

1,282,718

     

335,363

 

Transaction costs

   

139,342

     

151,305

 

Change in fair value of contingent consideration

   

(7,899,644)

     

-

 

Stock-based compensation expense

   

7,543,223

     

5,509,404

 

Income tax provision

   

(4,608,985)

     

8,977,231

 

Goodwill impairment charges

   

15,388,546

     

-

 

Adjusted EBITDA

 

$

(3,097,093)

   

$

51,586,236

 

 

Reconciliation of net income (loss) to adjusted net income (loss):

 
   

Years Ended December 31,

 
   

2022

   

2021

 

Net income (loss)

 

$

(14,238,249)

   

$

36,658,564

 

Goodwill impairment charges

   

15,388,546

     

-

 

Adjusted net income (loss)

 

$

1,150,297

   

$

36,658,564

 

 

 
 

SOURCE Co-Diagnostics

For further information: Company Contact: Andrew Benson, Head of Investor Relations, +1 801-438-1036, investors@codiagnostics.com; Investor Relations Contact: Zachary Mizener, Lambert & Co., +1 616-258-5804, zmizener@lambert.com

Join Our Newsletter

Receive our latest blog posts directly in your inbox!